Psoriasis meds may quietly shield arteries, small study hints
NCT ID NCT07169682
First seen Jun 25, 2026 · Last updated Jun 26, 2026 · Updated 1 time
Summary
This study checked if newer psoriasis drugs (IL17/23 inhibitors) also improve artery stiffness, a sign of heart disease. Researchers followed 66 people with moderate-to-severe psoriasis for a year, measuring pulse wave velocity (PWV) and other markers. The goal was to see if these drugs might have hidden heart benefits beyond clearing skin.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- IL17 or IL23 inhibitor (drug)
- What this could lead to
- If the drugs improve artery stiffness, it could suggest they also lower heart disease risk in people with psoriasis.
- What could go wrong
- This is a small, observational study, not a large trial. It only measured a marker (artery stiffness), not actual heart attacks or strokes, so the real benefit is uncertain.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ATHEROSCLEROSIS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Andreas Sygros Hospital
Athens, 17124, Greece
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a new gel calm psoriasis Flare-Ups?
- Can a Once-Daily cream tame psoriasis in toddlers?
- Putting Patients' priorities first: a new approach to ease the burden of multiple chronic illnesses
- A new multi-test approach may spot hidden blood vessel damage before symptoms appear
- Can a switch to guselkumab clear stubborn psoriasis?
- Can a new biologic clear stubborn psoriasis?